Norstella’s Post

Norstella introduces NorstellaLinQ: https://ow.ly/nqga50TGawG. It's biopharma’s first fully integrated data asset combining RWD—open and closed claims, lab results and EMR—with Norstella’s proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data. Get closer to the patient than ever before. Learn more about NorstellaLinQ at the link in this post.

NorstellaLinQ supports multiple teams across biopharma. Get closer to the patient than ever before. https://ow.ly/F0Yx50TN3Kg Learn more about NorstellaLinQ from Norstella at the link in this post. #Pipeline2Patient #FollowNorstella

WEBINAR: Register today: https://ow.ly/qU8H50TMI8X. Join SMEs from Norstella and Quest Diagnostics on Tuesday, Oct. 29, at 11 a.m. ET to learn how to leverage lab data to its full potential, leading to improved patient access and time to treatment.

2025 promises to represent another rich year of progress. https://ow.ly/V10q50TKMxG A wealth of new therapies are set to successfully graduate from the pipeline. Within this cohort are a mixture of therapeutic areas, drug classes, first-time approvals, label expansions, and, most importantly, treatments that will meaningfully change how diseases are treated. This article provides a snapshot of these advancements and the potential new approvals to add to your vocabulary, from apitegromab to Zegalogue. Click the link in this post to read the article.

“NorstellaLinQ isn’t just about bringing together data,” said Mike Gallup, CEO of Norstella. https://ow.ly/pNyS50TGeO0 “It’s about creating the only solution in the market that links real-world patient data with the proprietary intelligence of Citeline, Evaluate, MMIT, Panalgo and The Dedham Group that have powered the pharmaceutical industry for decades.” Get closer to the patient than ever before. Learn more about NorstellaLinQ by Norstella at the link in this post. Citeline, Evaluate Ltd, MMIT (Managed Markets Insight & Technology), Panalgo, The Dedham Group #Pipeline2Patient #FollowNorstella

Employee Spotlight Series: Meet Sarah Howard! https://ow.ly/xai850TwPOi We are delighted to spotlight Sarah Howard, our exceptional Commercial Support Manager for Norstella's Evaluate Ltd. Since 2007, Sarah has been a cornerstone of our team, expertly managing sales support and contract reviews to ensure everything runs smoothly and legally. In her new role within the commercial operations team, Sarah continues to provide invaluable support to our sales and commercial teams. Learn more about Sarah’s journey and contributions to Norstella in this Q&A on our blog.

Accelerate your path from pipeline to patient. https://ow.ly/p63i50TEB7O NorstellaLinQ connects 74 billion data points, paving the way for breakthroughs in drug development and commercialization. - Insights of 500,000 investigators - Tens of thousands of clinical trials across 185 countries - Hundreds of brand launches - Tens of thousands of forecasts Get closer to the patient than ever before. Learn more about NorstellaLinQ from Norstella at the link in this post.

In 2023, the biopharma industry broke records by investing a staggering $300 billion in research and development. However, with economic pressures mounting, there's a need for a shift. Rising costs and tighter budgets demand that the industry innovate more efficiently. Pharma must find ways to achieve more with less by adopting strategies and technologies that boost efficiency, cut costs, and continue to drive significant innovation for patients and the broader healthcare community. Check out the article: https://ow.ly/6qvC50TAkBq.

Norstella's CEO, Mike Gallup, weighs in on the launch of NorstellaLinQ in MM+M. Check it out: https://lnkd.in/ebqpAdhp.